Advertisement
U.S. markets close in 4 hours 21 minutes

Abbott Laboratories (ABL.DE)

XETRA - XETRA Delayed Price. Currency in EUR
113.50+1.28 (+1.14%)
At close: 04:56PM CET
Full screen
Previous Close112.22
Open112.32
Bid113.54 x 69000
Ask113.76 x 78000
Day's Range111.66 - 113.70
52 Week Range90.00 - 114.14
Volume233
Avg. Volume570
Market Cap197.758B
Beta (5Y Monthly)0.72
PE Ratio (TTM)36.03
EPS (TTM)3.15
Earnings DateJan 22, 2025 - Jan 27, 2025
Forward Dividend & Yield2.09 (1.86%)
Ex-Dividend DateOct 15, 2024
1y Target EstN/A
  • GlobeNewswire

    InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

    MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta

  • PR Newswire

    Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis

    Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical developm